The central question: does your knee actually need replacing?

Not every knee that hurts needs replacing. That is the starting point for many patients referred for an orthopaedic opinion — and the answer almost always turns on one question: how widespread is the damage?

Total knee replacement is designed for joints where cartilage has broken down across most or all of the joint surface — what clinicians describe as diffuse, end-stage disease, sometimes called bone-on-bone wear. For those patients, resurfacing the whole joint is often the only realistic option. Kellgren-Lawrence Grade IV osteoarthritis sits firmly in that category, and nothing discussed here changes that.

A different picture emerges when the damage is a contained patch — a single, bounded area of cartilage loss rather than widespread deterioration across the joint. These focal defects do not inevitably progress to whole-joint replacement, particularly if the surrounding cartilage is still healthy. Yet they cause real pain, functional limitation, and without intervention, may worsen over time.

ChondroFiller® liquid (commercially known as Liquid Cartilage™) is an injectable collagen scaffold developed specifically for this focal group — patients whose cartilage damage may be treatable without resurfacing the joint at all.

Who qualifies for the ChondroFiller pathway

The critical distinction is between a single damaged patch and widespread wear — and most of that assessment comes down to imaging and clinical examination.

ChondroFiller® is designed for focal, contained Grade III or IV chondral defects — isolated areas of full-thickness or near-full-thickness cartilage loss up to 6 cm² in size, surrounded by healthy cartilage borders. Typical candidates include patients with post-traumatic cartilage injuries, sports-related chondral lesions, or early-to-moderate focal wear where the rest of the joint surface remains largely intact.

Several factors influence candidacy beyond the defect itself:

• Lower-limb alignment — significant varus or valgus malalignment shifts load onto the repair site and may need addressing first or alongside treatment.
• Ligament stability — a mechanically unstable knee is a relative contraindication; instability should be assessed and, where possible, corrected before proceeding.
• Body weight — elevated BMI increases joint load, though the published data do not define a precise threshold, so individual assessment is needed.

The procedure is not appropriate for Kellgren-Lawrence Grade IV diffuse osteoarthritis, where joint-surface loss is widespread rather than focal. Those patients are better served by joint replacement options.

MRI — ideally using cartilage-sensitive sequences — is central to confirming defect size, containment, and the condition of the underlying subchondral bone. A clinical assessment will determine whether the imaging picture and patient factors together support the ChondroFiller pathway.

How ChondroFiller works in the knee

Placed directly into the damaged area of the joint during an outpatient appointment, ChondroFiller® liquid is an acellular scaffold — meaning it contains no donor cells of any kind. The material itself is a highly purified Type I collagen derived from murine sources, CE-marked as a Class III medical device. Under ultrasound guidance, the liquid is injected into the prepared focal defect, where it self-gels within approximately 3–5 minutes, bonding to the surrounding cartilage and subchondral bone to form a stable three-dimensional matrix.

From that point, the body does the biological work. The scaffold acts as a chemotactic signal, drawing mesenchymal progenitor cells from the synovium and surrounding tissue into its structure — a process known as acellular matrix-induced chondrogenesis. Those recruited cells differentiate progressively into chondrocytes and begin laying down new extracellular matrix. Over the following months the collagen scaffold itself is gradually broken down and cleared by the body; by 12–24 months it has been fully bioresorbed and replaced by the patient's own hyaline-like cartilage tissue.

The practical implication of this mechanism is that the treatment supports the body's own repair processes rather than substituting an external material or transplanted cells. No second appointment for cell harvesting is required, and nothing synthetic or permanent is left behind in the knee.

What the clinical results show

Four separate knee clinical studies report IKDC score improvements of approximately 30 points — consistently above the validated Minimal Clinically Important Difference of 16.7 points, meaning patients noticed a real functional change rather than a statistical shift. The most detailed dataset, a prospective post-market follow-up study by Jerosch et al., recorded a mean gain of 32.4 IKDC points sustained at three years, with patients reaching an average functional score of 80.

Structural repair is visible on MRI as well as felt by patients. MOCART scores in European knee cohorts ranged from 81.6 to 84.3, indicating greater than 80% defect filling with good peripheral integration. Scores progressed from 65.3 at four weeks to 81.6 at one year — a trajectory that documents ongoing biological maturation rather than an early imaging artefact.

The safety record across these cohorts includes a reported complication rate of approximately 0% and a reoperation rate of 3–8%. For context, microfracture — the most widely used marrow-stimulation comparator — carries a reoperation rate of up to 41%.

The primary evidence base derives from manufacturer-sponsored investigations. No independent, large-scale randomised controlled trials comparing this pathway directly with knee replacement have been published. The consistency across four separate studies and the objective MRI maturation trajectory are clinically meaningful — but the published knee literature currently extends to a three-year follow-up horizon. Patients considering this pathway should ask their consultant directly what durability data exist beyond that window, and how the evidence applies to their specific defect, age, and activity goals.

How it stacks up against other cartilage treatments

Against microfracture — the most widely used marrow-stimulation technique — ChondroFiller addresses a meaningfully wider range of defect sizes (up to 6 cm² versus fewer than 2–4 cm²) and produces hyaline-like repair tissue rather than the fibrocartilage that marrow stimulation typically yields. The durability gap follows from that tissue difference: reoperation rates for microfracture run as high as 41%, compared with 3–8% for the collagen scaffold pathway.

Cell-based therapies such as ACI and MACI produce hyaline-like tissue and achieve similar functional gains to ChondroFiller — the same approximate 30-point IKDC improvement, confirming rough parity in outcome — but they do so across two surgical stages, with complication rates reported up to 17% and reoperation rates up to 37%. Achieving comparable results in a single outpatient session represents a substantial reduction in procedural complexity and recovery burden.

Knee replacement occupies an entirely different position on the treatment ladder — it is not a head-to-head comparator. Arthroplasty answers diffuse, advanced joint disease; ChondroFiller targets a contained focal defect within a joint that is otherwise structurally sound. The clinical logic is sequential rather than competitive: in the eligible patient, a successful scaffold pathway may defer or remove the need for replacement, rather than rival it as a concept.

Recovery timeline and what to expect

Recovery follows three distinct phases. The first six weeks prioritise protecting the scaffold: weight-bearing is limited and movement kept controlled to allow the gel to bond and early cell migration to begin. Between weeks six and twelve, progressive loading resumes alongside physiotherapy aimed at restoring muscle strength around the joint. Beyond twelve weeks, activity increases gradually — functional improvement is typically well under way before the twelve-month mark.

The scaffold bioresorption timeline and the three-year outcome data from Jerosch et al. are covered in the sections above. What that evidence does not yet establish is how the repair holds beyond three years in large, independent knee cohorts. Body weight, lower-limb alignment, and ligament stability all influence individual results, but these factors are not fully quantified in the data currently available.

For a patient who has been told that replacement is inevitable, the most useful question may be a narrower one: is the damage truly diffuse across the whole joint surface, or is it confined to an isolated patch within an otherwise intact knee? That distinction — not the severity of pain alone — is what determines whether a joint-preserving pathway belongs in the conversation at all. Imaging and a structured clinical assessment can answer it. Lincolnshire Knee accepts patients without referral; details and bookings are at lincolnshireknee.co.uk.